<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView &amp;noscript=1">
Brand New Medical Study

Access potential vaccine for Respiratory Syncytial Virus (RSV)

📢 We are investigating a potential new vaccine for Respiratory Syncytial Virus (RSV)

In order to be considered to take part in the study, you’ll need to meet all of the following:

✔️ You are aged 60 to 80 years old, inclusive

✔️ You are generally healthy or have stable chronic health conditions

✔️ You have been fully-vaccinated against COVID-19

If that sounds like you, we would like to invite you to take part in our latest study investigating a potential vaccine! Simply register using the form on this page

about_1
📝 Registration Form
If you take part in the research study you will receive:

Reimbursement of costs

For out-of-pocket expenses, such as travel and meals.

Free study-related medical care

You may gain access to new potential vaccines, before they may become widely available.

No overnight stays!

All study visits are out-patient only.

🏥 Study Guide

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:

  • You are aged between 60 and 80 years old
  • You are generally healthy, or you have a stable chronic disease
  • You have a body mass index (BMI) of 40 or less (click here for a BMI calculator)
  • You have been fully-vaccinated against COVID-19


Who is unable to take part in this study?

Unfortunately, if you meet any of the following, this study is not the right fit for you:

  • Anyone who has a known or suspected immunosuppressive condition
  • Anyone with a history of a serious reaction to any prior vaccinations
  • Anyone with a history of any chronic respiratory illnesses


How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study is expected to last up to 62 weeks. This includes:

  • A screening period of up to 14 days 
  • Up to 3 vaccinations over a 4-8 week period
  • Approximately a 4-8 week vaccination period
  • A 12 month follow-up period

 

What is Respiratory Syncytial Virus (RSV)?

RSV is a common respiratory virus which affects the lungs and the smaller passageways that carry air to the lung. RSV is one of the most common causes of childhood illness, infecting most children by two years of age, however RSV can also infect adults.

Severe infection with RSV can lead to pneumonia (an infection in the lungs) and bronchiolitis (inflammation of the small airways in the lungs) and may require hospitalisation. People at greatest risk of severe infection are the very young (those less than six months old), those over the age of 65 and those of any age who have heart or lung conditions or a weakened immune system.

 

Where is my nearest study site?

Here is a map of all of the sites who are currently recruiting for this study:

What if I have other questions about the study?

We are here for you! Click or tap this button to send an email to our Patient Experience team:

📝 Registration Form